Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Markt

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
BMJ (Clinical Research Ed.)|December 15, 2016
Sniffing out significant "Pee values": genome wide association study of asparagus anosmiaSarah C Markt, Elizabeth Nuttall, Constance Turman, et al.
Cancer|March 14, 2022
Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid dataSiran M Koroukian, Guangjin Zhou, Suparna M Navale, et al.
The Prostate|August 25, 2020
Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trialEmily K Wiggins, Taofik Oyekunle, Lauren E Howard, et al.
Sleep Medicine|May 28, 2026
Sodium-relevant comorbidity risk factors are highly prevalent in individuals with narcolepsy or idiopathic hypersomniaSarah C Markt, Caroleen Drachenberg, Richard J Kovacs, et al.
The Prostate|April 16, 2021
Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer riskLatifa A Bazzi, Lara G Sigurdardottir, Sigurdur Sigurdsson, et al.
Cancer|June 11, 2019
Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik studyBarbra A Dickerman, Johanna E Torfadottir, Unnur A Valdimarsdottir, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 23, 2021
Urinary 6-sulfatoxymelatonin Levels and Prostate Cancer Risk among Men in the Multiethnic CohortJane B Vaselkiv, Iona Cheng, Ilkania M Chowdhury-Paulino, et al.
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
International Journal of Cancer|November 9, 2017
Midlife metabolic factors and prostate cancer risk in later lifeBarbra A Dickerman, Johanna E Torfadottir, Unnur A Valdimarsdottir, et al.
Carcinogenesis|October 19, 2023
SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysisSai Harisha Rajanala, Anna Plym, Jane B Vaselkiv, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
BMJ (Clinical Research Ed.)|December 15, 2016
Sniffing out significant "Pee values": genome wide association study of asparagus anosmiaSarah C Markt, Elizabeth Nuttall, Constance Turman, et al.
Cancer|March 14, 2022
Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid dataSiran M Koroukian, Guangjin Zhou, Suparna M Navale, et al.
The Prostate|August 25, 2020
Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trialEmily K Wiggins, Taofik Oyekunle, Lauren E Howard, et al.
Sleep Medicine|May 28, 2026
Sodium-relevant comorbidity risk factors are highly prevalent in individuals with narcolepsy or idiopathic hypersomniaSarah C Markt, Caroleen Drachenberg, Richard J Kovacs, et al.
The Prostate|April 16, 2021
Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer riskLatifa A Bazzi, Lara G Sigurdardottir, Sigurdur Sigurdsson, et al.
Cancer|June 11, 2019
Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik studyBarbra A Dickerman, Johanna E Torfadottir, Unnur A Valdimarsdottir, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 23, 2021
Urinary 6-sulfatoxymelatonin Levels and Prostate Cancer Risk among Men in the Multiethnic CohortJane B Vaselkiv, Iona Cheng, Ilkania M Chowdhury-Paulino, et al.
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
International Journal of Cancer|November 9, 2017
Midlife metabolic factors and prostate cancer risk in later lifeBarbra A Dickerman, Johanna E Torfadottir, Unnur A Valdimarsdottir, et al.
Carcinogenesis|October 19, 2023
SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysisSai Harisha Rajanala, Anna Plym, Jane B Vaselkiv, et al.
Pageof 8